Trial unpredictability yields predictable therapy gains

Benjamin Djulbegovic (), Ambuj Kumar, Paul Glasziou, Branko Miladinovic and Iain Chalmers
Additional contact information
Benjamin Djulbegovic: University of South Florida (USF), Tampa, and at the H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Ambuj Kumar: USF and at the H. Lee Moffitt Cancer Center and Research Institute.
Paul Glasziou: Paul Glasziou is professor of evidence-based medicine at Bond University, Robina, Australia.
Branko Miladinovic: USF.
Iain Chalmers: Iain Chalmers is coordinator of the James Lind Initiative, Oxford, UK.

Nature, 2013, vol. 500, issue 7463, 395-396

Abstract: In decades of clinical-trial data, new treatments are better than standard ones just over half the time. That's as it should be, say Benjamin Djulbegovic and colleagues.

Date: 2013
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/500395a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:500:y:2013:i:7463:d:10.1038_500395a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/500395a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().